Baltruškevičienė, E. (2016) “Significance of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer patients receiving Bevacizumab: a single institution experience”, Acta medica Lituanica, 23(1), pp. 24–34. doi:10.6001/actamedica.v23i1.3267.